Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Turcot syndrome 1Neoplasm Metastasis 1Medulloblastoma 1Glioma 1Familial ependymoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Brain Neoplasms 1

Interventions

Temozolomide 15Filgrastim 13Cyclophosphamide 9Carboplatin 9Granulocyte Colony-Stimulating Factor 7Etoposide 7Thiotepa 5Peripheral Blood Stem Cell Transplantation 5Melphalan 5Vorinostat 4Busulfan 4sonidegib 3ribociclib 3Vincristine 3Topotecan 3O(6)-benzylguanine 3Magnetic Resonance Spectroscopy 3Irinotecan 3Automobiles 3veliparib 2sargramostim 2pembrolizumab 2fludarabine 2etoposide phosphate 2Valproic Acid 2Thalidomide 2Surgical Procedures, Operative 2Stem Cell Transplantation 2Specimen Handling 2Radiotherapy, Intensity-Modulated 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Medulloblastoma × Diffusion Tensor Imaging × Clear all
NCT02359565 2026-05-13

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
71 enrolled
CNSGastrointestinal

Familial ependymoma, Turcot syndrome, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ependymoma, Glioma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡